Jefferies rates Endo at buy

Endo Pharmaceuticals Holdings Inc. was given a buy rating from Jefferies & Co., Inc. analyst David Windley. Jefferies estimates a 30 cent impact on 2006 earnings per share from the loss of oxycodone ER. Endo's late stage pipeline should help soften the impact. Shares of the Chadds Ford, Pa., pharmaceutical company were down $1.98, or 6.90%, at $26.72 on volume of 12,531,538 shares versus the three-month running average of 1,230,350 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.